EZH2 and congenital rubella syndrome: Although tazemetostat (enhancer of Zeste homolog 2 [EZH2] inhibitor), mosunetuzumab (CD20xCD3 bispecific T-cell engager antibody), and chimeric antigen receptor (CAR)-T therapies represent major advances in three or later lines R/R FL treatment, such issues, like cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and secondary T-cell malignancies of CAR-T therapies,27 still raise wide concerns.